What Are The Symptoms Of The Comt Val Met Variation?

The COMT Val158Met variation is a common genetic difference that affects how quickly your brain clears dopamine, a chemical tied to mood, focus, and pain perception. People with the Val/Val version have faster enzyme activity, which means less dopamine lingers in the brain’s frontal lobes. People with the Met/Met version have slower activity, which means more dopamine stays available. The symptoms most often discussed with this variation are not medical diseases but patterns of thinking, stress response, and pain sensitivity that differ depending on which version you carry.

What Are The Symptoms Of The Comt Val Met Variation?

The symptoms are not like a cold or a deficiency. There is no standard symptom checklist that applies to everyone with this gene variation. Instead, researchers describe two broad patterns based on whether you inherited two Val versions, two Met versions, or one of each.

People with two Val versions tend to have better baseline cognitive performance under calm conditions but struggle more under stress. They often show increased anxiety in high-pressure situations and may have a higher pain threshold. People with two Met versions tend to perform worse on some memory and attention tasks at baseline but perform better under stress. They also tend to have a lower pain threshold and may be more sensitive to discomfort.

Being a carrier of one Val and one Met version typically places you somewhere in between. Most people fall into this middle group, and for them, the practical symptoms are often minimal or unnoticeable in daily life.

How Does The COMT Gene Affect Brain Chemistry?

The COMT gene provides instructions for an enzyme called catechol-O-methyltransferase. This enzyme breaks down dopamine, norepinephrine, and epinephrine — three chemicals that influence mood, attention, alertness, and the stress response.

The Val158Met variation changes one amino acid in this enzyme. The Val version works faster, so it clears dopamine quickly. The Met version works about three to four times slower. This difference is most significant in the prefrontal cortex, the brain region responsible for planning, decision-making, and impulse control.

In the prefrontal cortex, dopamine levels need to stay in a narrow range. Too little dopamine impairs working memory and focus. Too much dopamine also impairs these functions. This is known as the inverted-U model of dopamine signaling. The Val and Met versions sit on different sides of that curve, which explains why neither version is clearly “better” overall.

What Cognitive Symptoms Are Linked To Each Version?

Studies have found that people with the Val/Val genotype often show slightly better performance on tasks that require sustained attention and working memory under normal, low-stress conditions. Their faster dopamine clearance keeps levels in an optimal range for these tasks.

Under stress, the picture changes. Stress itself increases dopamine release. In Val/Val carriers, the fast-clearing enzyme can push dopamine levels too low during stressful events, leading to a measurable drop in cognitive flexibility and working memory. Some research suggests Val/Val carriers also show stronger emotional responses to negative images and may ruminate more after a stressful event.

People with the Met/Met genotype often show the opposite pattern. At baseline, their slower enzyme can leave dopamine levels slightly above the optimal range, which some studies link to reduced performance on certain attention tasks. But when stress raises dopamine further, Met/Met carriers sometimes show preserved or even improved cognitive performance. This has led researchers to describe Met carriers as more resilient to stress-related cognitive decline, though the effect sizes in studies are modest.

How Does This Variation Affect Stress And Anxiety?

The COMT variation has been studied extensively in relation to anxiety and stress reactivity. The evidence here is more consistent than for cognitive performance.

Val/Val carriers, on average, show higher cortisol responses to acute psychological stress. They also tend to score higher on measures of trait anxiety. One explanation is that lower prefrontal dopamine reduces the brain’s ability to regulate the amygdala, the region that processes fear and threat. Without enough dopamine to keep the amygdala in check, threat responses can become exaggerated.

Met/Met carriers generally show a more moderate stress response. Their higher baseline dopamine in the prefrontal cortex appears to provide better top-down control over the amygdala. Some research has even linked the Met/Met version to lower scores on neuroticism and better emotional regulation. However, this does not mean Met/Met carriers never feel anxious. It means their average stress reactivity is lower.

One important point: the effect sizes in these studies are small. This gene variation explains only a small fraction of why one person is anxious and another is calm. Environment, life experiences, and dozens of other genes play larger roles.

Does This Variation Affect Pain Sensitivity?

Yes, and this is one of the more clinically relevant findings. The COMT enzyme also breaks down enkephalins, which are natural pain-relieving chemicals. Slower enzyme activity means enkephalins last longer, which dampens pain signals.

Multiple studies have found that Met/Met carriers report higher pain sensitivity. They rate experimental pain as more intense and show lower pain tolerance. This has been shown in studies using heat, cold, and pressure pain. Some research also suggests Met/Met carriers are at higher risk for developing chronic pain conditions like temporomandibular joint disorder and fibromyalgia.

Val/Val carriers, by contrast, tend to have higher pain thresholds and may tolerate pain better. However, the relationship is not simple. Some studies have found that Val carriers experience more pain-related distress in chronic pain settings, possibly because their lower dopamine levels reduce natural pain inhibition over time.

This variation also appears to influence how people respond to pain medications. Some research suggests Met carriers may need lower doses of certain opioids, while Val carriers may need higher doses. This area of study is still emerging, and no clinical guidelines currently recommend genetic testing for pain management based on COMT status alone.

Are There Behavioral Or Psychiatric Symptoms?

Researchers have investigated links between COMT variation and several psychiatric conditions, but the evidence is mixed and often inconsistent across studies.

Some studies have found a higher frequency of the Val/Val version in people with schizophrenia, particularly in relation to cognitive symptoms. Other studies have not replicated this finding. The relationship appears to depend on other genetic and environmental factors.

For mood disorders, the picture is similarly unclear. Some research suggests Val/Val carriers may be more vulnerable to depression after stressful life events. Other studies have found no such link. A meta-analysis of multiple studies found no strong association between COMT variation and major depression overall.

One area with more consistent findings is obsessive-compulsive disorder. Some studies have found a higher frequency of the Val/Val version in people with OCD, especially in males. Again, the effect is small, and not all studies agree.

It is important to be direct here: having a particular COMT version does not mean you will develop any psychiatric condition. The variation shifts risk by a small amount, and only in combination with many other factors.

Should You Get Tested For This Variation?

Direct-to-consumer genetic tests often include the COMT Val158Met variation. Knowing your version can be interesting and may help you understand patterns in how you respond to stress or pain. But it is not a diagnostic test.

No medical organization currently recommends routine COMT testing for any condition. The evidence does not support using this variation alone to predict disease risk, guide medication choices, or determine treatment plans. Some clinicians in the fields of psychiatry and pain medicine consider COMT status as one piece of a broader assessment, but this is not standard practice.

If you are considering genetic testing, it is worth knowing that the results are probabilistic, not deterministic. A Met/Met result does not mean you will have chronic pain. A Val/Val result does not mean you will develop anxiety. These are small shifts in tendency, not predictions.

What Should You Actually Do With This Information?

Useful, evidence-based actions do not depend on knowing your COMT status. Stress management techniques, regular physical activity, adequate sleep, and a balanced diet are beneficial regardless of which version you carry.

Physical exercise, in particular, has been shown to improve prefrontal dopamine function and cognitive performance. This may be especially helpful for Val/Val carriers, who tend to have lower baseline prefrontal dopamine. Mindfulness-based stress reduction has also shown benefits for people with high stress reactivity, which is more common in Val/Val carriers.

For pain management, knowing you are a Met carrier might encourage you to be more proactive about non-drug pain treatments like physical therapy, heat and cold therapy, and gradual activity pacing. But no specific diet, supplement, or lifestyle intervention has been proven to change COMT enzyme activity in a clinically meaningful way.